NewsBenzingaBristol Myers Squibb presenta los resultados de 56 semanas del ensayo clínico de fase 3 SCOUT-HCM en una presentación de última hora en las Sesiones Científicas de HCMS Bristol Myers Squibb presenta los resultados de 56 semanas del ensayo clínico de fase 3 SCOUT-HCM en una presentación de última hora en las Sesiones Científicas de HCMS Benzinga 2026.11.06 21:01 (GMT+0) Open on Benzinga Other news Morning Bid: Jensen Huang's last hurrah, and a nervy future for Nvidia 'Business as usual': Nvidia's Kress passes first test as board slams door on Huang Ethereum spot ETFs see total net outflow of $29.0903M yesterday, marking 3 consecutive days of net outflows Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders ‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors First American Financial Corporation (FAF) Presents at 2026 Stephens Annual Investment Conference | NASH2026 Transcript
Ethereum spot ETFs see total net outflow of $29.0903M yesterday, marking 3 consecutive days of net outflows
Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders
‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors
First American Financial Corporation (FAF) Presents at 2026 Stephens Annual Investment Conference | NASH2026 Transcript